Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...